Lucitanib

德立替尼

Report date: 2024/11/21 20:00:04
NME

Base Information

Drug NameLucitanib
Drug Alias Name卢他尼布LucitanibumDelitinib鲁西他尼Lucitanib hydrochloride +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[8] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[8] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursGenital Neoplasms, Female +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAdvenchen Laboratories Nanjing Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEthical Oncology ScienceShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
Inactive CompaniesBristol Myers Squibb SrlcompanyClovis Oncology IncInstitut De Recherches Internationales Servier +[7] 
Active IndicationsThymus NeoplasmsStomach NeoplasmsNasopharyngeal Carcinoma +[4] 
Inactive IndicationsMetastatic breast cancerSolid tumoursGenital Neoplasms, Female +[8] 

Other Information

ATC CodeN/A
Related LinksWikipedia